Evidence map›Paper›PMID 27567054›Full record

ArticleThe Lancet. Oncology2016

Preventable fractions of cervical cancer via effective screening in six Baltic, central, and eastern European countries 2017-40: a population-based study.

Salvatore Vaccarella, Silvia Franceschi, David Zaridze, Mario Poljak, Piret Veerus, Martyn Plummer, Freddie Bray

Open access · bronzeAbstract read
In one paragraph

Article in The Lancet. Oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Current Status of the National Cancer Screening Program in Korea: History, Achievements, and Future Directions.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2025
    Article
  8. Article
  9. Article
  10. Evidence of Decreased Long-term Risk of Cervical Precancer after Negative Primary HPV Screens Compared with Negative Cytology Screens in a Longitudinal Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024
    Article
  11. IRTKS contributes to the malignant progression of cervical cancer cells.Medical oncology (Northwood, London, England) · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. LncRNA HOTAIR enhances RCC2 to accelerate cervical cancer progression by sponging miR-331-3p.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Salvatore VaccarellaInternational Agency for Research on Cancer, Lyon, France. Electronic address: vaccarella@iarc.fr.
Silvia FranceschiInternational Agency for Research on Cancer, Lyon, France.
David ZaridzeRussian NN Blokhin Cancer Research Centre, Moscow, Russia.
Mario PoljakInstitute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
Piret VeerusEstonian Cancer Screening Registry, National Institute for Health Development, Estonia.
Martyn PlummerInternational Agency for Research on Cancer, Lyon, France.
Freddie BrayInternational Agency for Research on Cancer, Lyon, France.
Centre International de Recherche sur le Cancer · FRNational Institute for Health Development · EERussian Cancer Research Center NN Blokhin · RUUniversity of Ljubljana · SI

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundCervical cancer incidence remains high in several Baltic, central, and eastern European (BCEE) countries, mainly as a result of a historical absence of effective screening programmes. As a catalyst for action, we aimed to estimate the number of women who could be spared from cervical cancer across six countries in the region during the next 25 years, if effective screening interventions were introduced.

methodsIn this population-based study, we applied age-period-cohort models with spline functions within a Bayesian framework to incidence data from six BCEE countries (Estonia, Latvia, Lithuania, Belarus, Bulgaria, and Russia) to develop projections of the future number of new cases of cervical cancer from 2017 to 2040 based on two future scenarios: continued absence of screening (scenario A) versus the introduction of effective screening from 2017 onwards (scenario B). The timespan of available data varied from 16 years in Bulgaria to 40 years in Estonia. Projected rates up to 2040 were obtained in scenario A by extrapolating cohort-specific trends, a marker of changing risk of human papillomavirus (HPV) infection, assuming a continued absence of effective screening in future years. Scenario B added the effect of gradual introduction of screening in each country, under the assumption period effects would be equivalent to the decreasing trend by calendar year seen in Denmark (our comparator country) since the progressive regional introduction of screening from the late 1960s.

findingsAccording to scenario A, projected incidence rates will continue to increase substantially in many BCEE countries. Very high age-standardised rates of cervical cancer are predicted in Lithuania, Latvia, Belarus, and Estonia (up to 88 cases per 100 000). According to scenario B, the beneficial effects of effective screening will increase progressively over time, leading to a 50-60% reduction of the projected incidence rates by around 2040, resulting in the prevention of cervical cancer in 1500 women in Estonia and more than 150 000 women in Russia. The immediate launch of effective screening programmes could prevent almost 180 000 new cervical cancer diagnoses in a 25-year period in the six BCEE countries studied.

interpretationBased on our findings, there is a clear need to begin cervical screening in these six countries as soon as possible to reduce the high and increasing incidence of cervical cancer over the next decades.

fundingNone.

Indexed as

Early Detection of CancerAdultAgedEurope, EasternFemaleHumansMiddle AgedPapillomavirus VaccinesUterine Cervical NeoplasmsVaccinationPapillomavirus Vaccines

Identifiers

PMID27567054
PMCPMC5052457
OpenAlexW2513940906

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.